Updating results

221 results

Sort: Relevance | Date

Rapid tests for group A streptococcal infections in people with a sore throat (DG38)

Evidence-based recommendations on rapid tests for group A streptococcal (strep A) infections in people aged 5 and over with a sore throat

Diagnostics guidance Published November 2019

Tests in secondary care to identify people at high risk of ovarian cancer (DG31)

Evidence-based recommendations on tests (IOTA ADNEX, Overa, RMI I, ROMA, IOTA Simple Rules) in secondary care to identify people at high risk of ovarian cancer

Diagnostics guidance Published November 2017

Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (DG29)

Evidence-based recommendations on multi frequency bioimpedance devices to guide fluid management for people with chronic kidney disease having dialysis

Diagnostics guidance Published June 2017

Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care (DG30)

Evidence-based recommendations on quantitative faecal immunochemical tests (OC Sensor, HM-JACKarc and FOB Gold) to guide GP referral for colorectal cancer

Diagnostics guidance Published July 2017

Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (DG14)

Evidence-based recommendations on point-of-care coagulometers (the CoaguChek XS system) to self-monitor blood clotting

Diagnostics guidance Published September 2014 Last updated December 2017

Integrated multiplex PCR tests for identifying gastrointestinal pathogens in people with suspected gastroenteritis (xTAG Gastrointestinal Pathogen Panel, FilmArray GI Panel and Faecal Pathogens B assay) (DG26)

Evidence-based recommendations on integrated multiplex polymerase chain tests for identifying gastrointestinal pathogens in suspected gastroenteritis

Diagnostics guidance Published January 2017

New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners (DG3)

Evidence-based recommendations on new generation computed tomography (CT) scanners for cardiac imaging for suspected or known coronary artery disease

Diagnostics guidance Published January 2012 Last updated July 2017

Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (DG28)

Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy

Diagnostics guidance Published May 2017

Biomarker tests to help diagnose preterm labour in women with intact membranes (DG33)

Evidence-based recommendations on biomarker tests (Actim Partus, PartoSure, Rapid fFN 10Q Cassette) to diagnose preterm labour in women with intact membranes

Diagnostics guidance Published July 2018

Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I (DG32)

Evidence-based recommendations on DYSIS colposcope with DYSISmap and ZedScan I for assessing suspected cervical abnormalities in people having colposcopy

Diagnostics guidance Published April 2018

Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)

Evidence-based recommendations on immunohistochemistry/microsatellite instability testing to guide tests for Lynch syndrome in people with colon cancer

Diagnostics guidance Published February 2017

Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (DG35)

Evidence-based recommendations on lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care

Diagnostics guidance Published May 2019

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)

Evidence-based recommendations on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer

Diagnostics guidance Published December 2018

Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)

Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis

Diagnostics guidance Published July 2019

Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (DG37)

Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast

Diagnostics guidance Published November 2019

Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) (TA608)

NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults

Technology appraisal guidance Published October 2019

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

Evidence-based recommendations on rucaparib (Rubraca) for relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer that has responded to

Technology appraisal guidance Published November 2019

Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults

Technology appraisal guidance Published November 2019

Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) (TA549)

NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence

Technology appraisal guidance Published December 2018

Decitabine for untreated acute myeloid leukaemia (terminated appraisal) (TA548)

NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was

Technology appraisal guidance Published December 2018

Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)

NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from

Technology appraisal guidance Published March 2019

Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA444)

NICE is unable to make a recommendation about the use in the NHS of afatinib for advanced squamous non-small-cell lung cancer after platinum-based chemotherapy

Technology appraisal guidance Published May 2017

Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)

Evidence-based recommendations on pomalidomide (Imnovid) for multiple myeloma previously treated with lenalidomide and bortezomib in adults

Technology appraisal guidance Published January 2017

Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

Evidence-based recommendations on pembrolizumab (Keytruda) for locally advanced or metastatic PD-L1-positive non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published January 2017 Last updated September 2017

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

Technology appraisal guidance Published December 2016

Dinutuximab beta for treating neuroblastoma (TA538)

Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over

Technology appraisal guidance Published August 2018

Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course

Technology appraisal guidance Published March 2018

Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) to treat multiple sclerosis in adults

Technology appraisal guidance Published June 2018

Guselkumab for treating moderate to severe plaque psoriasis (TA521)

Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published June 2018

Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)

Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia

Technology appraisal guidance Published July 2019

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA559)

Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma

Technology appraisal guidance Published January 2019

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)

Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up 25 years

Technology appraisal guidance Published December 2018

Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for type 2 diabetes in adults

Technology appraisal guidance Published June 2019

Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults

Technology appraisal guidance Published March 2019

Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic (secondary) non-squamous non-small-cell lung cancer in adults after

Technology appraisal guidance Published November 2017

Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy

Technology appraisal guidance Published November 2017

Obinutuzumab for untreated advanced follicular lymphoma (TA513)

Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults

Technology appraisal guidance Published March 2018

Brodalumab for treating moderate to severe plaque psoriasis (TA511)

Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published March 2018

Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over

Technology appraisal guidance Published October 2019

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease

Technology appraisal guidance Published March 2011 Last updated June 2018

Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

Technology appraisal guidance Published October 2008 Last updated February 2018

Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)

NICE is unable to recommend the use in the NHS of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer..

Technology appraisal guidance Published December 2011 Last updated March 2017

Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

Evidence-based recommendations on raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

Technology appraisal guidance Published October 2008 Last updated February 2018

Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) (TA564)

NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive

Technology appraisal guidance Published February 2019

Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)

NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the

Technology appraisal guidance Published March 2019

Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) (TA576)

NICE is unable to make a recommendation about the use in the NHS of bosutinib for untreated chronic myeloid leukaemia because no evidence submission was

Technology appraisal guidance Published April 2019

Padeliporfin for untreated localised prostate cancer (TA546)

Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults

Technology appraisal guidance Published November 2018

Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)

NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults

Technology appraisal guidance Published May 2019

Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published April 2017

Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) (TA435)

NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was

Technology appraisal guidance Published March 2017